Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W7D4 | ISIN: CA05156V1022 | Ticker-Symbol: IKAP
Frankfurt
01.11.24
21:49 Uhr
6,584 Euro
+0,058
+0,89 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
AURINIA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AURINIA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,5906,79013:05
6,6846,81801.11.

Aktuelle News zur AURINIA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.10.Aurinia Pharmaceuticals spotlights lupus nephritis drug8
28.09.Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 13.0%2
24.09.Aurinia Announces Approval Of LUPKYNIS In Japan8
24.09.Japan approves Aurinia's lupus nephritis treatment1
13.09.Aurinia Pharmaceuticals shares gain as co reports Board restructuring5
12.09.Aurinia Pharmaceuticals strukturiert Vorstand um und beruft neuen Direktor2
12.09.Aurinia Pharmaceuticals reshuffles board, adds new director1
12.09.Aurinia Pharmaceuticals Inc. - 8-K, Current Report1
06.09.H.C. Wainwright reiterates Buy rating on Aurinia Pharma shares7
13.08.Investor activism resurfaces at Aurinia after CEO's board role, exec pay lost majority support7
13.08.On behalf of Lucien Selce: Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board338Highlights Damning Annual General Meeting Results, Which Show That Four of the Company's Nine Directors Failed to Receive a Majority of the Votes Calls on the Company to Appoint Two Shareholder...
► Artikel lesen
01.08.Earnings call: Aurinia Pharmaceuticals sees 38% revenue growth in Q25
01.08.Aurinia Pharma beats Q2 estimates, narrows FY revenue guidance7
01.08.Aurinia Pharmaceuticals Inc. - 10-Q, Quarterly Report1
01.08.Aurinia Pharmaceuticals Inc. - 8-K, Current Report1
01.08.Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results138ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the second quarter and six months...
► Artikel lesen
31.07.Aurinia Pharma Q2 2024 Earnings Preview2
14.06.Aurinia Pharmaceuticals Inc. - 8-K, Current Report6
07.06.ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal483SEOUL, South Korea, June 7, 2024 /PRNewswire/ -- Dear Fellow Shareholders, ILJIN SNT Co., Ltd. ("ILJIN") is a long-standing investor of Aurinia Pharmaceuticals Inc. ("Aurinia" or...
► Artikel lesen
05.06.Aurinia Pharmaceuticals Inc.: Aurinia Presents Safety and Efficacy Profile of LUPKYNIS for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024292Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna...
► Artikel lesen
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1